Send to

Choose Destination
An Pediatr (Barc). 2019 Jan;90(1):56.e1-56.e9. doi: 10.1016/j.anpedi.2018.10.006.

[Immunisation schedule of the Spanish Association of Paediatrics: 2019 recommendations].

[Article in Spanish]

Author information

Hospital Materno-Infantil, Hospital Regional Universitario de Málaga, Grupo de Investigación IBIMA; Departamento de Pediatría y Farmacología, Facultad de Medicina, Universidad de Málaga, Málaga, España. Electronic address:
Centro de Salud de Llanera, Asturias, España; Departamento de Medicina, Universidad de Oviedo, Asturias, España.
Servicio de Pediatría, Hospital Costa del Sol, Marbella, Málaga, España.
Servicio de Pediatría, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, España; Facultad de Medicina, Departamento de Pediatría, Universidad Autónoma de Madrid, España.
Centro de Salud Nazaret, Valencia, España; FISABIO, Valencia, España.
Centro de Salud Delicias Sur, Zaragoza, España; Departamento de Pediatría, Facultad de Medicina, Universidad de Zaragoza, España.
Centro de Salud La Rivota, Alcorcón, Madrid, España.
Hospital Germans Trias i Pujol, Badalona, Barcelona, España; Facultad de Medicina, Universidad Autónoma de Barcelona, España.
Centro de Salud El Greco, Getafe, Madrid, España; Facultad de Medicina, Universidad Europea, Madrid, España.
Centro de Salud de Guanarteme, Las Palmas de Gran Canaria, España.
Hospital Universitario 12 de Octubre, Madrid, España; Facultad de Medicina, Departamento de Pediatría, Universidad Complutense de Madrid, España.


The Advisory Committee on Vaccines of the Spanish Association of Paediatrics annually publishes the immunisation schedule considered optimal for children resident in Spain, according to available evidence on current vaccines. As regards funded immunisations, the 2+1 strategy (2, 4, 11 months) with hexavalent (DTPa-IPV-Hib-HB) and 13-valent pneumococcal vaccines are recommended. Administration of the 6-year booster dose with DTPa is recommended, with a poliomyelitis dose for children who had received the 2+1 scheme, as well as Tdap vaccine for adolescents and pregnant women in every pregnancy between 27 and 32 weeks gestation. The 2-dose scheme should be used for MMR (12 months and 3-4 years) and varicella (15 months and 3-4 years). MMRV vaccine could be applied as the second dose. Vaccination against HPV is recommended in both genders, preferably at 12 years of age. A stronger effort should be made to improve vaccination coverage. The new 9-valent vaccine is now available, expanding the coverage for both genders. Tetravalent meningococcal vaccine (MenACWY) is recommended at 12 months and 12-14 years, with a catch-up up at 19 years of age. It is also recommended in infants older than 6 weeks of age with risk factors, or travellers to countries with high incidence of ACWY meningococcal serogroups. As regards non-funded immunisations, it is recommended meningococcal B vaccination, with a 2+1 schedule, and requests that it be included in the National Immunisation Program. Vaccination against rotavirus is recommended in all infants.


Adolescent; Adolescente; Calendario de vacunación; Child; Enfermedades inmunoprevenibles; Immunisation schedule; Infant; Lactante; Niño; Vaccine preventable diseases; Vaccines; Vacunas

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center